MicroRNA as potential biomarkers in Glioblastoma

Journal of Neuro-Oncology

Volumn 125, Issue 2, 2015, Pages 237-248

  Areeb, Zammam ^a   Stylli, Stanley S ^a,b   Koldej, Rachel ^a,b,c   Ritchie, David S ^a,b,c   Siegal, Tali ^d   Morokoff, Andrew P ^a,b   Kaye, Andrew H ^a,b   Luwor, Rodney B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

Biomarker; Glioblastoma; MicroRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; TEMOZOLOMIDE; TUMOR MARKER;

BLOOD; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROSPINAL FLUID; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CLASSIFICATION; BRAIN NEOPLASMS; GENETICS; METABOLISM;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MICRORNAS;

EID: 84945199706     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1912-0     Document Type: Review

References (111)

1. Goodenberger ML, Jenkins RB (2012) Genetics of adult glioma. Cancer Genet. 205(12):613–621
2. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet 379(9830):1984–1996
3. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8):756–784
4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812
5. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14(Suppl 5):v1–v49
6. Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB Jr, Bota DA (2015) Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. J Clin Neurosci. 22(1):35–39
7. Jones TS, Holland EC (2012) Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene 31(16):1995–2006
8. Drappatz J, Norden AD, Wen PY (2009) Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9(4):519–534
9. Cher L, Rosenthal MA, Drummond KJ, Dally M, Murphy M, Ashley D et al (2008) The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998–2000. J Clin Neurosci. 15(4):398–401
10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
11. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al (2000) A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593
12. Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78(4):1147–1155
13. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5):459–466
14. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007
15. Scherer HJ (1940) A critical review: the pathology of cerebral gliomas. J Neurol Psychiatry. 3(2):147–177
16. McDonald KL, Aw G, Kleihues P (2012) Role of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them? Front Neurol. 3:188
17. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772
18. van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120(3):297–304
19. Thuy MN, Kam JK, Lee GC, Tao PL, Ling DQ, Cheng M et al (2015) A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci 22(5):785–799
20. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A et al (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol. 12(1):49–57
21. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455(7216):1061–1068
22. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B et al (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41(8):899–904
23. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 16(6):748–754
24. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173
25. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110
26. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462–477
27. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522
28. Henriksen M, Johnsen KB, Olesen P, Pilgaard L, Duroux M (2014) MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme. Neuromol Med. 16(3):565–577
29. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20(3):539–550
30. Parker NR, Correia N, Crossley B, Buckland ME, Howell VM, Wheeler HR (2013) Correlation of MicroRNA 132 up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant temozolomide chemotherapy. Transl Oncol. 6(6):742–748
31. Brower JV, Clark PA, Lyon W, Kuo JS (2014) MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem Int 77:68–77
32. Low SY, Ho YK, Too HP, Yap CT, Ng WH (2014) MicroRNA as potential modulators in chemoresistant high-grade gliomas. J Clin Neurosci. 21(3):395–400
33. Mizoguchi M, Guan Y, Yoshimoto K, Hata N, Amano T, Nakamizo A et al (2013) Clinical implications of microRNAs in human glioblastoma. Front Oncol. 3:19
34. Hermansen SK, Kristensen BW (2013) MicroRNA biomarkers in glioblastoma. J Neurooncol 114(1):13–23
35. Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47(1):131–144
36. Piwecka M, Rolle K, Belter A, Barciszewska AM, Zywicki M, Michalak M et al (2015) Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol 9(7):1324–1340
37. Qu S, Guan J, Liu Y (2015) Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci 348(1–2):181–187
38. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H et al (2014) Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 533(1):389–397
39. Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S et al (2013) Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 112(2):153–163
40. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M et al (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68(10):3566–3572
41. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E et al (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69(19):7569–7576
42. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G et al (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68(22):9125–9130
43. Gu JJ, Gao GZ, Zhang SM (2015) miR-218 inhibits the migration and invasion of glioma U87 cells through the Slit2-Robo1 pathway. Oncol Lett. 9(4):1561–1566
44. Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL et al (2015) MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem 290(14):8938–8948
45. Rao SA, Santosh V, Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23(10):1404–1417
46. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16(16):4289–4297
47. Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Bacchi Reggiani ML et al (2014) Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. Mol Oncol. 8(2):417–430
48. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W et al (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46(9):1640–1649
49. Rivera-Diaz M, Miranda-Roman MA, Soto D, Quintero-Aguilo M, Ortiz-Zuazaga H, Marcos-Martinez MJ et al (2015) MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value. Am J Cancer Res. 5(1):201–218
50. Berthois Y, Delfino C, Metellus P, Fina F, Nanni-Metellus I, Al Aswy H et al (2014) Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O(6)-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther 15(7):938–950
51. Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D’Angelo V et al (2014) A miRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS ONE 9(10):e108950
52. Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I et al (2011) MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS ONE 6(5):e20600
53. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF et al (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 93(3):325–332
54. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602
55. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773
56. Lang MF, Yang S, Zhao C, Sun G, Murai K, Wu X et al (2012) Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS ONE 7(4):e36248
57. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N et al (2008) MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun. 376(1):86–90
58. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA et al (2010) Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol. 12(5):422–433
59. Srinivasan S, Patric IR, Somasundaram K (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PLoS ONE 6(3):e17438
60. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S et al (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119(4):814–824
61. Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C et al (2014) MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 5(24):12908–12915
62. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E et al (2011) MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 102(12):2186–2190
63. Ma R, Yan W, Zhang G, Lv H, Liu Z, Fang F et al (2012) Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PLoS ONE 7(6):e38096
64. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y (2013) Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 11:10
65. Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B (2012) Increased expression of microRNA-17 predicts poor prognosis in human glioma. J Biomed Biotechnol. 2012:970761
66. Lai NS, Dong QS, Ding H, Miao ZL, Lin YC (2014) MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci. 21(5):755–760
67. Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B (2013) Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol 15(7):569–574
68. Sun J, Shi H, Lai N, Liao K, Zhang S, Lu X (2014) Overexpression of microRNA-155 predicts poor prognosis in glioma patients. Med Oncol 31(4):911
69. Men D, Liang Y, Chen L (2014) Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients. Cancer Epidemiol. 38(2):152–156
70. Hou SX, Ding BJ, Li HZ, Wang L, Xia F, Du F et al (2013) Identification of microRNA-205 as a potential prognostic indicator for human glioma. J Clin Neurosci. 20(7):933–937
71. Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B (2013) Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol 30(1):373
72. Huang D, Qiu S, Ge R, He L, Li M, Li Y et al (2015) miR-340 suppresses glioblastoma multiforme. Oncotarget 6:9257–9270
73. Guan Y, Chen L, Bao Y, Pang C, Cui R, Li G et al (2015) Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma. Int J Clin Exp Pathol. 8(1):727–734
74. Chang C, Shi H, Wang C, Wang J, Geng N, Jiang X et al (2012) Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 531(2):204–208
75. Bracken CP, Li X, Wright JA, Lawrence DM, Pillman KA, Salmanidis M et al (2014) Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J 33(18):2040–2056
76. Stylli SS, Kaye AH, Lock P (2008) Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci. 15(7):725–737
77. Stylli SS, Stacey TT, Kaye AH, Lock P (2012) Prognostic significance of Tks5 expression in gliomas. J Clin Neurosci. 19(3):436–442
78. Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 5:55
79. Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71(9):3387–3399
80. Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q et al (2014) Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res. 33:9
81. Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA et al (2015) Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol. 9(3):704–714
82. Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A et al (2014) miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis 5:e1279
83. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E et al (2010) MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 57(3):264–269
84. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W et al (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 14(1):29–33
85. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M et al (2012) MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 14(6):689–700
86. Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y et al (2015) miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol 123(2):205–216
87. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S et al (2013) MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS ONE 8(10):e78115
88. Liu Y, Zhang J, Han R, Liu H, Sun D, Liu X (2015) Downregulation of serum brain specific microRNA is associated with inflammation and infarct volume in acute ischemic stroke. J Clin Neurosci. 22(2):291–295
89. Sun XY, Lu J, Zhang L, Song HT, Zhao L, Fan HM et al (2015) Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients. J Clin Neurosci. 22(3):570–574
90. Dong L, Li Y, Han C, Wang X, She L, Zhang H (2014) miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. Int J Oncol 45(2):746–756
91. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G et al (2011) A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118(3):449–457
92. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J et al (2012) Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 31:97
93. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F et al (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132(1):116–127
94. Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q et al (2014) Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. doi:10.1371/journal.pone.0105734
95. Shao N, Wang L, Xue L, Wang R, Lan Q (2015) Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 36(2):309–313
96. Ilhan-Mutlu A, Wagner L, Wohrer A, Furtner J, Widhalm G, Marosi C et al (2012) Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest 30(8):615–621
97. Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB et al (2015) Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer 112(Suppl):1241–1246
98. Zhang R, Pang B, Xin T, Guo H, Xing Y, Xu S et al (2015) Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma. Mol Neurobiol 48(1):37
99. Wu J, Li L, Jiang C (2014) Identification and evaluation of serum MicroRNA-29 family for glioma screening. Mol Neurobiol. 1:1–7
100. Wei X, Chen D, Lv T, Li G, Qu S (2014) Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. Mol Neurobiol. 50:896–913
101. Manterola L, Guruceaga E, Gallego Perez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Tejada S et al (2014) A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 16(4):520–527
102. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476
103. Siegal T (2015) Clinical impact of molecular biomarkers in gliomas. J Clin Neurosci. 22(3):437–444
104. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G et al (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 334(4):1351–1358
105. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033
106. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M et al (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14
107. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125(6):1407–1413
108. Hua D, Mo F, Ding D, Li L, Han X, Zhao N et al (2012) A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing. OMICS 16(12):690–699
109. Skalsky RL, Cullen BR (2011) Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE 6(9):e24248
110. Sana J, Radova L, Lakomy R, Kren L, Fadrus P, Smrcka M et al (2014) Risk score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. Carcinogenesis 35(12):2756–2762
111. Zadran S, Remacle F, Levine R (2014) Surprisal analysis of glioblastoma multiform (GBM) microRNA dynamics unveils tumor specific phenotype. PLoS ONE 9(9):e108171